Literature DB >> 8749907

Hepatotoxicity of chemotherapeutic and oncologic agents.

P D King1, M C Perry.   

Abstract

Problems arise in cancer chemotherapy when liver function tests are not normal, when drugs that possess known hepatic toxicity are to be given, and when abnormalities arise after drug administration. Most hepatotoxic drug reactions are idiosyncratic, occuring because of either hypersensitivity mechanisms or host metabolic idiosyncrasy. The clinician must always consider that liver injury is due to an idiosyncratic drug reaction, especially in a setting where patients typically receive many drugs, such as an oncology service. Chemotherapeutic agents often possess predictable, dose-dependent ("direct") hepatotoxicity, however. This article addresses the spectrum of hepatotoxic effects of chemotherapeutic agents. The hepatotoxic potential of single-agent as well as combination chemotherapy is discussed and recommendations for dose modifications in patients with impaired hepatic function are provided.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749907

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  5 in total

Review 1.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

2.  Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.

Authors:  Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

3.  Current challenges and controversies in drug-induced liver injury.

Authors:  Alberto Corsini; Patricia Ganey; Cynthia Ju; Neil Kaplowitz; Dominique Pessayre; Robert Roth; Paul B Watkins; Mudher Albassam; Baolian Liu; Saray Stancic; Laura Suter; Michele Bortolini
Journal:  Drug Saf       Date:  2012-12-01       Impact factor: 5.606

4.  Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.

Authors:  Liselot B J van Iersel; Ellen J Hoekman; Hans Gelderblom; Alexander L Vahrmeijer; Els L van Persijn van Meerten; Fred G J Tijl; Henk H Hartgrink; Peter J K Kuppen; Johan W R Nortier; Rob A E M Tollenaar; Cornelis J H van de Velde
Journal:  Ann Surg Oncol       Date:  2008-05-10       Impact factor: 5.344

5.  Evaluation of azathioprine-induced cytotoxicity in an in vitro rat hepatocyte system.

Authors:  Abdullah Al Maruf; Luke Wan; Peter J O'Brien
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.